Essential Thrombocythemia - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Essential Thrombocythemia - Pipeline Review, H2 2018’, provides an overview of the Essential Thrombocythemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Essential Thrombocythemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Essential Thrombocythemia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Essential Thrombocythemia

- The report reviews pipeline therapeutics for Essential Thrombocythemia by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Essential Thrombocythemia therapeutics and enlists all their major and minor projects

- The report assesses Essential Thrombocythemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Essential Thrombocythemia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Essential Thrombocythemia

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Essential Thrombocythemia pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AbbVie Inc

Aop Orphan Pharmaceuticals AG

F. Hoffmann-La Roche Ltd

Incyte Corp

Italfarmaco SpA

MEI Pharma Inc

Millennium Pharmaceuticals Inc

PharmaEssentia Corp

SELLAS Life Sciences ...

AbbVie Inc

Aop Orphan Pharmaceuticals AG

F. Hoffmann-La Roche Ltd

Incyte Corp

Italfarmaco SpA

MEI Pharma Inc

Millennium Pharmaceuticals Inc

PharmaEssentia Corp

SELLAS Life Sciences Group Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Essential Thrombocythemia - Overview

Essential Thrombocythemia - Therapeutics Development

Pipeline Overview

Pipeline ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Essential Thrombocythemia - Overview

Essential Thrombocythemia - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Essential Thrombocythemia - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Essential Thrombocythemia - Companies Involved in Therapeutics Development

AbbVie Inc

Aop Orphan Pharmaceuticals AG

F. Hoffmann-La Roche Ltd

Incyte Corp

Italfarmaco SpA

MEI Pharma Inc

Millennium Pharmaceuticals Inc

PharmaEssentia Corp

SELLAS Life Sciences Group Inc

Essential Thrombocythemia - Drug Profiles

anagrelide hydrochloride CR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

anagrelide hydrochloride PR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

givinostat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

idasanutlin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

peginterferon alfa-2a - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pevonedistat hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pracinostat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ropeginterferon alfa-2b - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ruxolitinib phosphate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Myeloproliferative Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target WT1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

veliparib ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Essential Thrombocythemia - Dormant Projects

Essential Thrombocythemia - Discontinued Products

Essential Thrombocythemia - Product Development Milestones

Featured News & Press Releases

Nov 15, 2017: Incyte Announces Initiation of Pivotal Clinical Trial of Ruxolitinib (Jakafi) for the Treatment of Essential Thrombocythemia

Nov 01, 2017: Incyte Highlights Jakafi Data at 59th Annual ASH Meeting

Dec 28, 2016: Galena Biopharma Confirms Regulatory Pathway for GALE-401 (Anagrelide Controlled Release)

Sep 12, 2016: Galena Biopharma Expands GALE-401 Intellectual Property Protection with Patent Issuance in Japan

Jun 13, 2016: Galena Biopharma Presents GALE-401 Combined Safety Data at the European Hematology Association 21st Congress

Nov 18, 2014: Galena Biopharma Completes Enrollment In GALE-401 (Anagrelide Controlled Release) Phase 2 Clinical Trial

Feb 13, 2013: Novartis's Myelofibrosis Drug Jakavi Turned Down By NICE In Draft Guidance

Dec 06, 2010: Incyte Presents Positive Phase II Trial Results Of INCB18424 In Advanced Polycythemia Vera And Essential Thrombocythemia At ASH Annual Meeting

May 28, 2009: Incyte Provides Update on Special Protocol Assessment for INCB18424 As A New Treatment for Myelofibrosis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Essential Thrombocythemia, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products ...

List of Tables

Number of Products under Development for Essential Thrombocythemia, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Essential Thrombocythemia - Pipeline by AbbVie Inc, H2 2018

Essential Thrombocythemia - Pipeline by Aop Orphan Pharmaceuticals AG, H2 2018

Essential Thrombocythemia - Pipeline by F. Hoffmann-La Roche Ltd, H2 2018

Essential Thrombocythemia - Pipeline by Incyte Corp, H2 2018

Essential Thrombocythemia - Pipeline by Italfarmaco SpA, H2 2018

Essential Thrombocythemia - Pipeline by MEI Pharma Inc, H2 2018

Essential Thrombocythemia - Pipeline by Millennium Pharmaceuticals Inc, H2 2018

Essential Thrombocythemia - Pipeline by PharmaEssentia Corp, H2 2018

Essential Thrombocythemia - Pipeline by SELLAS Life Sciences Group Inc, H2 2018

Essential Thrombocythemia - Dormant Projects, H2 2018

Essential Thrombocythemia - Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development for Essential Thrombocythemia, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products ...

List of Figures

Number of Products under Development for Essential Thrombocythemia, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports